Oculis Holding AG to Participate in June 2025 Investor Conferences

Avatar photo

Oculis Holding AG to Present at Key Investor Conferences in June

Oculis Holding AG will participate in investor conferences this June, with CEO Riad Sherif scheduled for presentations and one-on-one meetings.

Conference Details

The biopharmaceutical company, based in Switzerland, will attend the Goldman Sachs Annual Healthcare Conference and the J.P. Morgan European Healthcare Conference. CEO Dr. Riad Sherif will discuss the company’s focus on unmet medical needs, including treatments for diabetic macular edema and dry eye disease. Investors can arrange one-on-one meetings during these events by visiting the company’s website for more details.

Potential Positives

  • Participation in the Goldman Sachs and J.P. Morgan conferences may boost visibility and attract investors.
  • A fireside chat with CEO Riad Sherif will foster engagement with the investing community.
  • The company has a diverse pipeline targeting significant unmet medical needs, which could enhance investor confidence.

Potential Negatives

  • The absence of major product news at these conferences might raise concerns about the company’s pipeline.
  • Relying on one-on-one meetings for investor engagement could reflect limited investor confidence, affecting stock performance.

Frequently Asked Questions

What conferences will Oculis participate in June 2025?

Oculis will attend the Goldman Sachs Annual Healthcare Conference and the J.P. Morgan European Healthcare Conference.

Who will represent Oculis at these conferences?

Dr. Riad Sherif, Chief Executive Officer, will represent Oculis at both events.

When is the Oculis fireside chat scheduled?

The fireside chat is set for June 10th from 9:20 to 9:55 am ET.

How can investors request meetings with Oculis?

Investors can request meetings through their representatives at the sponsoring institutions of the conferences.

Where can I find Oculis webcast links for the events?

Webcast links will be available on the Oculis website in the Events & Presentation section under Investors & Media.

$OCS Hedge Fund Activity

In the most recent quarter, 18 institutional investors added shares of $OCS, while 3 reduced their holdings.

Recent significant moves include:

  • PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC acquired 563,078 shares (+32.4%) in Q1 2025, totaling approximately $10,715,374.
  • SR ONE CAPITAL MANAGEMENT, LP gained 322,500 shares in Q1 2025, valued at about $6,137,175.
  • ABRDN PLC added 188,871 shares (+23.0%) in Q4 2024, worth around $3,210,807.
  • ALYESKA INVESTMENT GROUP, L.P. purchased 131,332 shares in Q1 2025, estimated at $2,499,247.
  • ACUTA CAPITAL PARTNERS, LLC increased holdings by 125,000 shares in Q1 2025, for an estimated $2,378,750.
  • NAN FUNG GROUP HOLDINGS LTD acquired 78,324 shares (+17.9%) in Q1 2025, worth around $1,490,505.
  • CITADEL ADVISORS LLC divested 22,911 shares (-100.0%) in Q1 2025, totaling approximately $435,996.

For detailed tracking of hedge fund activity, visit Quiver Quantitative’s institutional holdings dashboard.

Full Release

ZUG, Switzerland, June 3, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) has announced participation in the following investor conferences:

Goldman Sachs Annual Healthcare Conference

June 9-11; Miami, FL, U.S.

Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET.

J.P. Morgan European Healthcare Conference

June 12; London, U.K.

Riad Sherif, MD, Chief Executive Officer, will attend.

The Company will be open for one-on-one meetings during these conferences. Interested investors should contact representatives at the sponsoring institutions for requests.

Webcast links will be provided on the Oculis website under the Events & Presentation section for the Investors & Media.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; ICX: OCS) developing novel solutions for ophthalmic and neuro-ophthalmic diseases. Key products include OCS-01 for diabetic macular edema (DME) and OCS-02, a topical biologic anti-TNFα drop for dry eye disease. Headquartered in Switzerland, the company operates in the U.S. and Iceland, led by an experienced team backed by prominent healthcare investors.

For more information, visit:
www.oculis.com

Oculis Contacts

Ms. Sylvia Cheung, CFO
[email protected]

Investor Relations

LifeSci Advisors
Corey Davis, Ph.D.
[email protected]

Media Relations

ICR Healthcare
Amber Fennell / David Daley / Sean Leous
[email protected]

This article was originally published on Quiver News.

The views in this article are those of the author and do not reflect Nasdaq, Inc.

The free Daily Market Overview 250k traders and investors are reading

Read Now